New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
08:16 EDTCELGAcceleron receives two FDA orphan designations for ACE-536
Acceleron Pharma announced that the FDA granted orphan designation for ACE-536 for the treatment of beta-thalassemia and for the treatment of myelodysplastic syndromes, two rare blood disorders characterized by severe and chronic anemia. ACE-536 is an investigational protein therapeutic that increases red blood cells through a novel mechanism and is being developed by Acceleron as part of a global collaboration with Celgene Corporation.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent CELG news | >>
July 15, 2015
07:46 EDTCELGCelgene acquisition of Receptos will be viewed favorably, says Baird
Baird believes Celgene's (CELG) acquisition of Receptos (RCPT) will be viewed favorably by the Street, as the firm sees the price as attractive enough to move the needle for Celgene in the long term. Baird reiterated its Outperform rating and raised its price target to $162 from $139 on Celgene shares.
07:43 EDTCELGReceptos volatility flat into Celgene acquiring for $7.2B
Subscribe for More Information
07:09 EDTCELGCelgene may face rival bidder for Receptos, says Wedbush
Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos (RCPT), which has agreed to a $232 per share takeover deal with Celgene (CELG), noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Receptos' Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos, who told investors she sees "plenty" of potential upside to justify a rival bidder stepping in, reiterated the firm's Outperform rating and $348 acquisition value on Receptos shares.
07:04 EDTCELGCelgene volatility low into acquiring Receptos for about $7.2B
Subscribe for More Information
06:28 EDTCELGCelgene price target raised to $175 from $160 at Deutsche Bank
Subscribe for More Information
05:59 EDTCELGPiper views Receptos buyout as good for Arena
Piper Jaffray analyst Edward Tenthoff views Celgene's (CELG) acquisition of Receptos (RCPT) as good for Arena Pharmaceuticals (ARNA). Tenthoff views Arena as a "derivative call" on the deal with the company's APD334 already showing dose-dependent decreases in circulating lymphocyte counts. Arena will also initiate Phase II studies in ulcerative colitis and Crohn's disease this year, the analyst points out. Receptos' ozanimod is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. Tenthoff reiterates an Overweight rating on Arena with a $7.50 price target. The company has a market capitalization around $1B and closed yesterday up 8c to $4.47
05:52 EDTCELGReceptos deal 'another good move' for Celgene, says Piper Jaffray
Subscribe for More Information
July 14, 2015
19:05 EDTCELGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CSX (CSX), up 3.5%. ALSO HIGHER: Receptos (RCPT), up 10.2% following deal to be acquired by Celgene (CELG)... Celgene is up 5.8% after announcing acquisition of Receptos... Celsion (CLSN), up 8.8% after being initiated with a Buy at BTIG... Aratana Therapeutics (PETX), up 10% after results of pivotal study of AT-003. DOWN AFTER EARNINGS: Peregrine (PPHM), down 3%... Yum! Brands (YUM), down marginally. ALSO LOWER: Allegheny Technologies (ATI), down 9.3% after providing second quarter EPS guidance... Mead Johnson (MJN), down 4.8% after reducing fiscal 2015 EPS guidance.
18:18 EDTCELGCelgene sees Receptos team staying on board following acquisition
Subscribe for More Information
18:08 EDTCELGImmuno-oncolgy stocks advance after Receptos acquired by Celgene
Subscribe for More Information
18:07 EDTCELGCelgene sees Receptos deal accretive in 2019
18:06 EDTCELGCelgene downplays regulatory concerns in Receptos deal, sees closing in Q3
Subscribe for More Information
17:31 EDTCELGReceptos up about 10% following deal to be acquired by Celgene
Subscribe for More Information
17:30 EDTCELGCelgene up about 5% after announcing acquisition of Receptos
Subscribe for More Information
17:09 EDTCELGCelgene raises 2020 adjusted EPS view to exceed $13.00, up from prior $12.50
Subscribe for More Information
17:06 EDTCELGCelgene reports preliminary Q2 adjusted EPS approximately $1.23, consensus 1.14
Subscribe for More Information
17:04 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
17:02 EDTCELGCelgene to acquire Receptos for $232 per share in cash, or about $7.2B
Subscribe for More Information
16:59 EDTCELGCelgene to acquire Receptos for $232 per share in cash
July 13, 2015
07:35 EDTCELGRegeneron price target rasied to $650 from $455 at Deutsche Bank
Deutsche Bank analyst Robyn Karnauskas raised her price target for Regeneron Pharmaceuticals (REGN) to $650 saying the run in the shares is not over. Her previous price target was $455. The biopharmaceutical company closed Friday up $16.98 to $526.01. Karnauskas notes that while Celgene (CELG) is her top pick in biopharma, she sees 25% upside for Regeneron with "many" near-term catalysts. The company's antibody business continues to grow while investors are underestimating Dupilimab, a drug with Phase 3 data this year, Karnauskas tells investors this morning in a research note. Dupilumab, a monoclonal antibody designed for the treatment of atopic diseases, could be a $10B-plus opportunity for Regeneron, according to the analyst. She keeps a Buy rating on the shares.
1 | 2 | 3 | all recent CELG news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use